CDIO - התחייבויות לטווח ארוך להון cardiodiagnosticsinc.com

Cardio Diagnostics (CDIO) is implementing an innovative AI-driven epigenetic screening method for cardiac pathologies, enabling the company to maintain significant pricing power. Demand for these tests remains independent of economic cycles and seasonality, while insurance reimbursements guarantee financial stability. Although sample logistics have been outsourced to partners, the core DNA analysis algorithms remain proprietary, ensuring independence. The indicator stands at 0.02. The market dynamics reflected in the price action are presented below.

The resilience of Cardio Diagnostics (CDIO) depends on the balance between borrowed funds and equity. This indicator compares liabilities with a maturity of over one year against the net asset value. By analyzing financial leverage regarding long-term debt, an investor assesses bankruptcy risk against return potential. A liquidity buffer is critical for the implementation of AI diagnostics for cardiovascular pathologies. A low ratio confirms the fair value of the business amidst market shocks.